Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) had its target price lifted by LADENBURG THALM/SH SH from $4.00 to $10.00 in a research report released on Tuesday morning, The Fly reports. A number of other equities analysts also recently commented on CRVS. Mizuho restated a neutral rating and issued a $3.50 target price on shares of […]
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 455,500 shares, a growth of 209.2% from the April 30th total of 147,300 shares. Approximately 1.3% of the shares of the company are sold […]
StockNews.com assumed coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research report report published on Thursday morning. The firm issued a hold rating on the stock. CRVS has been the subject of several other research reports. Cantor Fitzgerald raised their price target on Corvus Pharmaceuticals from $2.00 to $4.00 in a […]
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) Director Linda Grais bought 10,000 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were bought at an average cost of $2.45 per share, with a total value of $24,500.00. Following the completion of the transaction, the director now owns 10,000 shares […]
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) Director Linda Grais acquired 10,000 shares of the business’s stock in a transaction on Monday, May 15th. The stock was purchased at an average cost of $2.45 per share, with a total value of $24,500.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s […]